The results of the fifth batch of national centralized purchasing are analyzed in 4 figures
June 26, 2021
The fifth batch of national procurement with volume (hereinafter referred to as "this national procurement") was carried out in Shanghai the day before yesterday, and the results of the proposed selection were publicized. According to CCTV reports, there are 355 drug bids from 201 pharmaceutical companies, and 251 products from 148 pharmaceutical companies are to be selected, with an average decrease of 56%. One product (propranolol oral regular release dosage form) is the second choice. There are many varieties and large market scale involved in the national procurement, especially the fierce competition of injections. The enthusiasm and effectiveness of foreign enterprises to participate in the bidding are significantly improved, 11 products of 10 foreign enterprises are to be selected. The day before the bidding (June 21), the author published "bid opening the day after tomorrow | challenges for the fifth batch of national procurement, chemical and pharmaceutical injections", which predicted the possible performance of this centralized procurement of injections and foreign enterprises, and basically coincided with the results of the proposed selection.
Variety 1、 Price reduction
Although the price reduction rate has been eased since the fourth batch of Guocai "taking into account the reasonable profits of enterprises", and the winning price below 10 cents is rare, the competition is still very fierce because there are a lot of injections this time, and the injections can only be sold in hospitals, and the procurement period has been extended from only one year of the previous batches to 1-3 years. According to incomplete statistics, among the 251 varieties to be selected, 29 varieties with a price reduction rate of more than 90%, accounting for more than 10%, and the highest reduction rate is 98.3% (rivaroxaban). As shown in Figure 1, among the 22 varieties with a price reduction rate of more than 92%, 17 varieties are injection.
2、 Enterprises to be selected
Since the rules for conformity evaluation of chemical drug injections were issued on May 14 last year, pharmaceutical enterprises have accelerated the speed of conformity batch evaluation. Starting from the fourth batch of Guocai, the upper limit of the number of enterprises allowed to win the bid has increased from the previous 8 to 10. This time, 10 enterprises have won the bid for esomeprazole, ceftriaxone, ceftazidime and rivaroxaban tablets, Injection accounts for more than half of the 23 varieties with more than 4 successful enterprises.
Enterprise 1、 Number of selected products
On November 29, 2019, the State Council's leading group for deepening health care reform issued several policies and measures on further deepening the reform of the medical and health system by taking the centralized purchase and use of drugs as a breakthrough point, which proposed that "accelerate the formation of a drug production and circulation pattern with large backbone enterprises as the main body and small and medium-sized enterprises as the supplement", Qilu, Zhengda Tianqing, Kelun, Yangzijiang and other large pharmaceutical enterprises won the most number of bidding varieties. Among them, 11 of Qilu won the bid, 10 of the other three won the bid, and 27 of them won three or more bidding varieties.
2、 Performance of foreign enterprises
This country's foreign enterprises' participation in the enterprise has been greatly improved in its enthusiasm and effectiveness. A total of 10 foreign enterprises have won 11 varieties, 7 of which are injections, and the price reduction is also very awesome. 6 varieties have dropped more than 70%, and the Cephalon injection of benzdulmine hydrochloride has dropped to 87%.
The market scale involved in the fifth batch of procurement with volume is huge, which further dispels the fluke mentality of pharmaceutical enterprises on procurement with volume. Even foreign enterprises have deepened their understanding of the normalization and institutionalization of procurement with volume and put it into action. The impact of this centralized procurement on the pharmaceutical industry will also rise to a new height, the concentration of the pharmaceutical industry will continue to improve, and the strategic adjustment of pharmaceutical enterprises will also accelerate.
